Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
herpes zoster vaccine (recombinant, adjuvanted)
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The herpes zoster vaccine (recombinant, adjuvanted), marketed under the brand name Shingrix, is a non-live, recombinant subunit vaccine developed by GSK for the prevention of herpes zoster (shingles) and post-herpetic neuralgia. It is indicated for adults aged 50 years and older, as well as adults aged 18 years and older who are at increased risk of herpes zoster due to immunodeficiency or immunosuppression (such as those undergoing autologous hematopoietic stem cell transplantation). The vaccine consists of recombinant varicella-zoster virus (VZV) glycoprotein E (gE), the most abundant surface glycoprotein of VZV, formulated with the liposome-based AS01B Adjuvant System (containing 3-O-desacyl-4'-monophosphoryl lipid A [MPL] and QS-21). This formulation enhances both CD4+ T-cell and humoral immune responses to prevent VZV reactivation. It is administered intramuscularly as a two-dose regimen.
- Brand names
- Shingrix
- Other names
- herpes zoster gE/AS01B candidate vaccinerecombinant zoster vaccineRZVherpes zoster glycoprotein E with AS01B adjuvant candidate vaccine
02
Targets
gE (VZV glycoprotein E)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on herpes zoster vaccine (recombinant, adjuvanted).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on herpes zoster vaccine (recombinant, adjuvanted).